An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk  

作　　者：Bin Xue Yifan Liu Min Zhang Gangfeng Xiao Xiu Luo Lili Zhou Shiguang Ye Yan Lu Wenbin Qian Li Wang Ping Li Aibin Liang 

机构地区：[1]Department of Hematology,Shanghai Tongji Hospital,Tongji University School of Medicine,Shanghai 200065,China [2]Department of Hematology,Ningbo No.2 Hospital,Ningbo,Zhejiang 315010,China [3]Department of Hematology,The Second Affiliated Hospital,College of Medicine,Zhejiang University,Hangzhou,Zhejiang 310009,China [4]Department of Hematology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200001,China

出　　处：《Chinese Medical Journal》2025年第1期108-110,共3页中华医学杂志(英文版)

基　　金：supported by grants from the National Key R&D Program of China(No.2021YFA1100800);National Natural Science Foundation of China(Nos.81830004 and 82070168);Translational Research Grant of NCRCH(No.2020ZKZC04);Shanghai Municipal Health Commission(No.2020CXJQ02);Cultivation project of National Natural Science Foundation of Shanghai Tongji Hospital(No.GJPY2332).

摘　　要：To the Editor:Autologous CD19 chimeric antigen receptor(CAR)T-cell therapy has emerged as a crucial treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma(r/r DLBCL).[1]While CAR-T-cell therapy has the potential for curing a subset of patients despite its high cost,over 60%of recipients eventually experience relapse.[2]This troubling statistic has led several clinical centers to investigate the underlying reasons for CAR-T-cell therapy failure or suboptimal outcomes.[3,4]Currently,a reliable method for predicting the curative efficacy of CAR-T cells is lacking.[5]In this study,we conducted a comprehensive analysis to identify various predictors influencing the success of CAR-T-cell therapy.Our efforts have culminated in the development of a predictive model designed to assess the therapeutic efficacy of CAR-T-cell therapy.

关 键 词：therapeutic efficacy chimeric antigen REFRACTORY predictive model Chimeric Antigen Receptor T cell therapy diffuse large B cell lymphoma 

分 类 号：R733.4[医药卫生—肿瘤] R73[医药卫生—临床医学]